Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190094 | 0.92 | MCHR1 (0.59) | ADRB2MCHR1GPR119USP30ALDH1A1 | |
| SCHEMBL321217 | 0.85 | ADRB2 (0.56) | ADRB2MCHR1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10244583 | 0.84 | ADRB2 (0.52) | ADRB2MCHR1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10190085 | 0.83 | MCHR1 (0.57) | MCHR1GPR119USP30DPP4HRH3 | |
| SCHEMBL321227 | 0.82 | KCNH2 (0.54) | ADRB2MCHR1GPR119USP30MEN1 | |
| SCHEMBL22266021 | 0.82 | GPR119 (0.55) | GPR119USP30ALDH1A1DPP4HRH3 | |
| SCHEMBL31312460 | 0.82 | GPR119 (0.55) | GPR119USP30ALDH1A1DPP4HRH3 | |
| SCHEMBL17009588 | 0.80 | ALDH1A1 (0.51) | GPR119ALDH1A1KDM4EDPP4MTNR1B | |
| SCHEMBL18983290 | 0.79 | MTNR1B (0.57) | ADRB2ALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL24117863 | 0.79 | GPR119 (0.56) | GPR119USP30DPP4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590969-B1 | Therapeutic agents 976 | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | EP | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-8546375-B2 | (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds | ASTRAZENECA AB (SE) | 2013-10-01 | — | — | US | disclosed |
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | ASTRAZENECA AB (SE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010189-A1 | (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS | TYR, MC2R, MC1R | ADRB2 184/4885MCHR1 9/4885GPR119 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.